Belldegrun's VC firm nabs a major $825M funding well for next-gen biotechs badams Thu, 06/24/2021 - 06:36.: After an illustrious career in biotech, including navigating Kite Pharma and then Allogene to become major players in the cell therapy space, Arie Belldegrun, M.D., and his new venture firm are looking to make a series of bets on the next big thing in biotech. Belldegrun’s third fund for Vida Venture, Vida III, has reeled in a massive $825 million, giving it a total of $1.7 billion under management from across all three funds.